PF-00610355

DRUG4 trials

Sponsors

Pfizer

Conditions

Asthma, BronchialBronchial DiseasesLung DiseaseLung DiseasesLung Diseases, ObstructiveMoxifloxacinPulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 1

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

CompletedNCT01107054

PfizerLung Disease, Moxifloxacin, Pulmonary Disease

Start: 2010-06-30End: 2010-12-31Updated: 2011-01-13

Phase 2

Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

CompletedNCT00783406

PfizerPulmonary Disease, Chronic Obstructive

Start: 2008-10-31End: 2009-03-31Target: 20Updated: 2010-11-01

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

CompletedNCT00808288

PfizerLung Diseases, Lung Diseases, Obstructive, Pulmonary Disease, Chronic Obstructive

Start: 2010-03-31End: 2010-12-31Updated: 2019-02-06

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

WithdrawnNCT00830427

PfizerAsthma, Bronchial, Bronchial Diseases, Lung Diseases, Obstructive +1

Start: 2009-04-15End: 2009-12-31Updated: 2019-01-31